Traxion Therapeutics Inc. is a biotech company focused on the development of novel drugs for the treatment of intractable pain, in particular neuropathic pain.

The company has a diversified portfolio of novel, proprietary small molecule products to address this market opportunity. These products use more selective, mechanism-based approaches that exploit recent scientific discoveries in order to develop more effective, better tolerated treatments for neuropathic pain.

Traxion plans to take these products through to Phase II proof of concept studies and then enter worldwide corporate partnerships for later-stage development and commercialization.